Nuclear PARP1 expression and its prognostic significance in breast cancer patients
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Nuclear PARP1 expression and its prognostic significance in breast cancer patients
Authors
Keywords
PARP1, BRCA1, Immunohistochemistry, Prognostic marker, Breast cancer
Journal
TUMOR BIOLOGY
Volume 37, Issue 5, Pages 6143-6153
Publisher
Springer Nature
Online
2015-11-27
DOI
10.1007/s13277-015-4465-0
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
- (2015) A. S. Coates et al. ANNALS OF ONCOLOGY
- PARP1 and phospho-p65 protein expression is increased in human HER2-positive breast cancers
- (2015) Jennifer Stanley et al. BREAST CANCER RESEARCH AND TREATMENT
- DNA damage response markers are differentially expressed in BRCA-mutated breast cancers
- (2015) Mohammed Aleskandarany et al. BREAST CANCER RESEARCH AND TREATMENT
- Olaparib Monotherapy in Patients With Advanced Cancer and a GermlineBRCA1/2Mutation
- (2015) Bella Kaufman et al. JOURNAL OF CLINICAL ONCOLOGY
- Expression of DNA Damage Response Molecules PARP1, γH2AX, BRCA1, and BRCA2 Predicts Poor Survival of Breast Carcinoma Patients
- (2015) See-Hyoung Park et al. Translational Oncology
- Biological and clinical significance of PARP1 protein expression in breast cancer
- (2014) Andrew R. Green et al. BREAST CANCER RESEARCH AND TREATMENT
- A novel crosstalk between BRCA1 and poly (ADP-ribose) polymerase 1 in breast cancer
- (2014) Da Li et al. CELL CYCLE
- Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial
- (2014) Jonathan Ledermann et al. LANCET ONCOLOGY
- An update on PARP inhibitors—moving to the adjuvant setting
- (2014) Amir Sonnenblick et al. Nature Reviews Clinical Oncology
- PARP1-Driven Poly-ADP-Ribosylation Regulates BRCA1 Function in Homologous Recombination-Mediated DNA Repair
- (2014) Y. Hu et al. Cancer Discovery
- Beyond Breast and Ovarian Cancers: PARP Inhibitors for BRCA Mutation-Associated and BRCA-Like Solid Tumors
- (2014) Ciara C. O’Sullivan et al. Frontiers in Oncology
- Poly (ADP-ribose) polymerase 1 protein expression in normal and neoplastic prostatic tissue
- (2013) M. Salemi et al. EUROPEAN JOURNAL OF HISTOCHEMISTRY
- Poly(ADP-ribose) Polymerase 1 Is a Key Regulator of Estrogen Receptor α-dependent Gene Transcription
- (2013) Fengxiao Zhang et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial
- (2013) Shahneen K Sandhu et al. LANCET ONCOLOGY
- HER2 Overexpression Renders Human Breast Cancers Sensitive to PARP Inhibition Independently of Any Defect in Homologous Recombination DNA Repair
- (2012) S. Nowsheen et al. CANCER RESEARCH
- Failure of Iniparib to Inhibit Poly(ADP-Ribose) Polymerase In Vitro
- (2012) A. G. Patel et al. CLINICAL CANCER RESEARCH
- Global estimates of cancer prevalence for 27 sites in the adult population in 2008
- (2012) Freddie Bray et al. INTERNATIONAL JOURNAL OF CANCER
- Secondary mutations inBRCA2associated with clinical resistance to a PARP inhibitor
- (2012) Louise J Barber et al. JOURNAL OF PATHOLOGY
- New insights into the molecular and cellular functions of poly(ADP-ribose) and PARPs
- (2012) Bryan A. Gibson et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer
- (2012) Jonathan Ledermann et al. NEW ENGLAND JOURNAL OF MEDICINE
- BRCAness Profile of Sporadic Ovarian Cancer Predicts Disease Recurrence
- (2012) Weiya Z. Wysham et al. PLoS One
- Loss of 53BP1 Causes PARP Inhibitor Resistance in Brca1 -Mutated Mouse Mammary Tumors
- (2012) Janneke E. Jaspers et al. Cancer Discovery
- Nuclear PARP-1 protein overexpression is associated with poor overall survival in early breast cancer
- (2011) F. Rojo et al. ANNALS OF ONCOLOGY
- PARP-1 expression in breast cancer including BRCA1-associated, triple negative and basal-like tumors: possible implications for PARP-1 inhibitor therapy
- (2011) Pawel Domagala et al. BREAST CANCER RESEARCH AND TREATMENT
- Cytoplasmic Poly(Adenosine Diphosphate–Ribose) Polymerase Expression Is Predictive and Prognostic in Patients With Breast Cancer Treated With Neoadjuvant Chemotherapy
- (2011) Gunter von Minckwitz et al. JOURNAL OF CLINICAL ONCOLOGY
- High Nuclear Poly(Adenosine Diphosphate-Ribose) Polymerase Expression Is Predictive forBRCA1- andBRCA2-Deficient Breast Cancer
- (2011) Luka Ozretić et al. JOURNAL OF CLINICAL ONCOLOGY
- Iniparib in Metastatic Triple-Negative Breast Cancer
- (2011) NEW ENGLAND JOURNAL OF MEDICINE
- Iniparib plus Chemotherapy in Metastatic Triple-Negative Breast Cancer
- (2011) Joyce O'Shaughnessy et al. NEW ENGLAND JOURNAL OF MEDICINE
- Novel Agents and Future Directions for Refractory Breast Cancer
- (2011) Harold J. Burstein SEMINARS IN ONCOLOGY
- Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
- (2010) Andrew Tutt et al. LANCET
- Classification and prognosis of invasive breast cancer: from morphology to molecular taxonomy
- (2010) Stuart J Schnitt MODERN PATHOLOGY
- The PARP Side of the Nucleus: Molecular Actions, Physiological Outcomes, and Clinical Targets
- (2010) Raga Krishnakumar et al. MOLECULAR CELL
- Declining Death Rates Reflect Progress against Cancer
- (2010) Ahmedin Jemal et al. PLoS One
- Inhibition of poly adenosine diphosphate-ribose polymerase decreases hepatocellular carcinoma growth by modulation of tumor-related gene expression
- (2009) Rosa Quiles-Perez et al. HEPATOLOGY
- Inhibition of Poly(ADP-Ribose) Polymerase in Tumors fromBRCAMutation Carriers
- (2009) Peter C. Fong et al. NEW ENGLAND JOURNAL OF MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now